Roivant Sciences Ltd. is a UK-based pharmaceutical company with a medium-risk ESG score of 27.5. Specializing in improving healthcare delivery, Roivant Sciences also supports discovery-stage companies and health tech startups aligned with its biopharmaceutical focus. Lead drug candidate VTAMA targets plaque psoriasis in adults, furthering Roivant's commitment to sustainable healthcare solutions. Additional candidates in various development stages include Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and more.